Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 2/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.44 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.44 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401329 | 0.81 | ADK (0.41) | ADKSRC | |
| SCHEMBL132511 | 0.76 | SRC (0.71) | CDK1SRCEGFRKDRABL1 | |
| SCHEMBL398621 | 0.75 | SRC (0.67) | CDK1SRCEGFRKDRABL1 | |
| SCHEMBL11926780 | 0.75 | DYRK3 (0.49) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 | |
| SCHEMBL16236616 | 0.74 | SRC (0.50) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 | |
| SCHEMBL29484487 | 0.74 | SRC (0.50) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 | |
| SCHEMBL12934038 | 0.73 | DYRK3 (0.50) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 | |
| SCHEMBL22430490 | 0.73 | DYRK3 (0.50) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 | |
| SCHEMBL401337 | 0.72 | SRC (0.45) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 | |
| SCHEMBL1585102 | 0.71 | ADK (0.49) | DYRK3PRKD3MAP4K4PRKACARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117597346-A | NEK7 inhibitors | 哈利亚治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | DYRK3 247/4885PRKD3 501/4885MAP4K4 97/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | DYRK3 580/4885PRKD3 224/4885MAP4K4 132/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | DYRK3 580/4885PRKD3 224/4885MAP4K4 132/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | DYRK3 247/4885PRKD3 501/4885MAP4K4 97/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | DYRK3 1578/4885PRKD3 568/4885MAP4K4 486/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | DYRK3 1271/4885PRKD3 792/4885MAP4K4 312/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | DYRK3 580/4885PRKD3 224/4885MAP4K4 132/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | DYRK3 247/4885PRKD3 501/4885MAP4K4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.